Republic of the Philippines
Department of Health
**FOOD AND DRUG ADMINISTRATION**

Food and Drug Administration PHILIPPINES

12 OCT 2020

**FDA ADVISORY No. 2020-1875**

**TO:** **ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

**SUBJECT:** **PUBLIC WARNING AGAINST DRUG PRODUCTS STOLEN FROM PASCUAL LABORATORIES, INC.**

---

The public is hereby warned by the Food and Drug Administration (FDA) to be vigilant about the drug products due for destruction last 28 August 2020 but were reported by Pascual Laboratories, Inc. as stolen from their waste treater, Cleanleaf International Corporation.

Below is the list of the drug products reported as part of theft:

| PRODUCT NAME | PACKAGING | REG. NO. | BATCH/ LOT NO. | EXPIRY DATE |
|---|---|---|---|---|
| Ascorbic Acid 500 mg Sugar-Coated Tablet **(Poten-Cee)** | Amber Blister pack x 10's (Box of 100's) | DR-9468 | **56SIE** | 04/30/2022 or 30-APR-2022 |
| Vitex Negundo L. (Lagundi Leaf) 600 mg/5 mL Syrup (Menthol) **(Ascof Forte)** | 120 mL Amber Bottle (Box of 1's) | HMR-19 | **320SEE** | 11/15/2022 or 15-NOV-2022 |
| | | | **320SIF** | 04/30/2022 or 30-APR-2022 |
| | | | **320SRE** | 12/13/2022 or 13-DEC-2022 |

The batch/lot numbers mentioned above are not guaranteed by the FDA to be stored according to Good Storage Practice (GSP). Thus, the safety, efficacy and quality of these batches/lots are also not assured. These present safety risk and potential adverse health consequences. Therefore, consumers are instructed not to purchase or use the drug products with the stated batch/lot numbers.

All Local Government Units (LGU) and Law Enforcement Agencies (LEAs) are requested to ensure that the affected product batches/lots are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at **cdrr_postmarketsurveillance@fda.gov.ph.** To report continuous sale or distribution of the abovementioned, kindly e-mail us via **ereport@fda.gov.ph**. You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. Any suspected adverse reaction experienced from the use of the product should be reported immediately to the FDA through this link: **https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH** and fill-out all of the required fields.

Dissemination of the information to all concerned is requested.

**ROLANDO ENRIQUE D. DOMINGO, MD**
Director General

20200909145249